Jun 10, 2026
17 MIN READ

The Evolution of GLP-1 Agonists: When Were They Approved?

GLP-1 receptor agonists emerged from diabetes research in the 1990s and transformed into precision weight loss tools by 2021. Understanding their approval history helps patients make informed decisions about modern metabolic therapy.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 10, 2026
17 MIN READ

the evolution of glp-1 agonists: when were they approved? — PlexusDx GLP-1 education

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Glucagon-like peptide-1 (GLP-1) agonists have roots stretching back nearly three decades, beginning as diabetes medications before becoming the foundation of contemporary weight management science. The first GLP-1 compound reached the market in 2005, but the weight loss revolution began in earnest when semaglutide received FDA approval for chronic weight management in 2021—marking a pivotal moment in metabolic medicine. PlexusDx now delivers compounded semaglutide injections starting at $149 per month, giving patients access to this clinically validated therapy without insurance barriers.

The Origins of GLP-1 Therapy: From Diabetes to Weight Loss

GLP-1 agonists were not invented for weight management—they emerged from endocrinologists' search for better diabetes control in the 1990s. Researchers studying the intestinal hormone GLP-1 discovered it could stimulate insulin release while simultaneously slowing gastric emptying and reducing hunger signals. This triple mechanism made the compounds powerful tools for blood sugar regulation, but early clinical trials revealed an unexpected benefit: patients consistently lost weight. The first approved GLP-1 drug, exenatide (Byetta), entered the U.S. market in April 2005 specifically as a type 2 diabetes medication, marking the official beginning of GLP-1 therapeutic history.

Between 2005 and 2020, additional GLP-1 compounds gained FDA approval primarily for glycemic control in diabetic patients. Liraglutide arrived in 2010, followed by dulaglutide in 2014, and extended-release versions of existing compounds that improved dosing convenience. Clinicians and patients noticed consistent weight loss as a secondary effect—some individuals dropping 5 to 10 pounds or more while taking these medications for blood sugar management. This observation catalyzed a new research direction: could GLP-1 agonists be specifically engineered and dosed for weight loss in non-diabetic populations? The answer emerged through large-scale clinical trials that would reshape obesity medicine.

Semaglutide's FDA Approval for Weight Management in 2021

Semaglutide represented the first GLP-1 agonist explicitly developed and approved for chronic weight loss in people without diabetes. In November 2021, the FDA authorized semaglutide (marketed as Wegovy at a higher dose) for weight management in adults with obesity or overweight with weight-related conditions. The approval followed the STEP trials—a series of rigorous clinical studies demonstrating that semaglutide-treated patients achieved average weight reductions of 10 to 17 percent of their baseline body weight over 68 weeks. This approval signified that GLP-1 therapy had evolved from a diabetes side effect into a primary, purposeful tool for metabolic disease, fundamentally changing how physicians approached long-term weight management.

The 2021 breakthrough triggered rapid scaling of GLP-1 accessibility, though supply constraints and high retail pricing limited initial patient access. PlexusDx recognized this gap and partnered with licensed 503A compounding pharmacies to deliver clinically equivalent semaglutide at transparent, flat monthly pricing—starting at just $149 per month without insurance requirements. This democratization of GLP-1 therapy means patients across all 50 states can now access the same mechanism that earned FDA approval, while PlexusDx's pricing commitment ensures monthly costs remain stable regardless of dose adjustments.

Key FDA Milestones in GLP-1 Development History

The regulatory timeline for GLP-1 agonists spans multiple decades and demonstrates how scientific understanding evolves. Exenatide (2005) opened the class for diabetes care, while liraglutide injection (Victoza) gained diabetes approval in 2010 and later received weight-loss indication approval in 2014 as Saxenda at higher doses. Dulaglutide (2014) and extended-release formulations followed, each adding clinical evidence and dosing options. Tirzepatide, a newer compound with dual GLP-1 and GIP receptor activity, received FDA diabetes approval in 2022 and weight management approval in 2023—representing the next evolutionary step beyond traditional GLP-1 monotherapy. PlexusDx now compounds both semaglutide and tirzepatide, allowing patients to access cutting-edge peptide science through a single integrated platform.

The approval progression also includes oral formulations: oral semaglutide gained FDA diabetes approval in 2019 and weight-loss approval in 2023, expanding convenience for patients who prefer tablets over injections. Each approval milestone incorporated longer-term safety data, dose-optimization studies, and evidence of sustained metabolic benefits. Understanding this timeline helps patients recognize that GLP-1 therapy represents mature, extensively studied science—not experimental treatment. PlexusDx Precision Peptide Genetic Test, offered at $99 after the first month of treatment, allows patients to map their individual peptide pathway variants (including GLP1R rs6923761 and MC4R rs17782313) to optimize their specific GLP-1 response.

How Compounded GLP-1 Access Continues the Evolution

The 2021–2023 approval wave for GLP-1 weight-loss medications created unprecedented demand, outpacing pharmaceutical supply chains and leaving many patients unable to access therapy despite medical necessity. Licensed 503A compounding pharmacies—regulated facilities that formulate medications under state pharmacy board and FDA oversight—stepped in to provide clinically equivalent alternatives. PlexusDx partners exclusively with 503A pharmacies (never 503B facilities, which serve hospitals and institutions) to ensure the same quality and sterility standards applied to brand-name GLP-1 products. Compounded semaglutide injections begin at $149 monthly, and oral semaglutide starts at $249 monthly—democratizing access while maintaining clinical standards.

Compounding also enables rapid iteration and personalization in ways that large pharmaceutical manufacturers cannot match at scale. PlexusDx now offers GLP-Squared injections (a dual semaglutide and tirzepatide compound) starting at $249 per month, and the Microdose GLP-1 Protocol at $129 monthly for patients beginning therapy or preferring conservative dosing. All products are HSA/FSA eligible and available across all 50 states without membership fees or insurance requirements. This accessibility continues the evolution that began in 2005: making GLP-1 therapy a standard tool rather than a luxury, and ensuring that approval and availability are two separate questions answered in favor of patients.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

When exactly was semaglutide approved for weight loss, not diabetes?

The FDA approved semaglutide (Wegovy) specifically for chronic weight management on November 4, 2021, for adults with obesity or overweight plus weight-related conditions. This marked the first GLP-1 agonist approved as a primary weight-loss medication rather than a diabetes side benefit. PlexusDx compounded semaglutide injection delivers the same active compound at $149 per month without insurance.

What clinical evidence supports GLP-1 weight loss after approval?

The STEP clinical trial program demonstrated semaglutide-treated patients achieved 10–17 percent body weight reduction over 68 weeks, compared to 2–3 percent with placebo. Tirzepatide (GIP/GLP-1 dual agonist) showed even greater reductions of 15–22 percent in the SURMOUNT trials. PlexusDx offers compounded tirzepatide injection starting at $249 monthly, bringing this breakthrough mechanism to broader populations.

Does PlexusDx pricing change as my GLP-1 dose increases?

No. PlexusDx uses flat monthly pricing for all GLP-1 medications—your dose may increase, but your price won't. Compounded semaglutide injection stays at $149 per month, and tirzepatide injection remains $249 monthly, regardless of dose escalation needed for your individual response.

Are compounded GLP-1 medications from PlexusDx as safe as FDA-approved brand versions?

PlexusDx partners exclusively with licensed 503A compounding pharmacies that meet strict FDA and state regulatory standards for sterility, potency, and quality—identical to brand-name pharmaceutical standards. Compounded medications contain the same active ingredient but are not FDA-approved individual products. All patients should work with PlexusDx healthcare providers to monitor safety and efficacy.

How does PlexusDx Precision Peptide Genetic Test personalize my GLP-1 therapy?

The $99 Precision Peptide Genetic Test (available after your first month of treatment) analyzes 14 metabolic pathways and 150+ genetic insights, including critical GLP-1 pathway variants like GLP1R rs6923761 and MC4R rs17782313. This helps PlexusDx clinicians predict your individual GLP-1 agonist responsiveness and optimize your specific compound choice—semaglutide, tirzepatide, or dual therapy.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves